This is a guest post by Oleksandr Topachevskyi at Digital Health Outcomes. Oleksandr may be contacted at sales@digitalho.com Commercial, nonprofit, and government companies are quite good at calculating the costs…
This article was originally published by Guy Shtar, Louise Azulay, Omer Nizri, Lior Rokach & Bracha Shapira in Scientific Data volume 9, Article number: 263 under a Creative Commons Attribution…
DrugPatentWatch has been named to Genetic Engineering News‘ Best of the Web list. The review by Genetic Engineering News profile highlighted the “new training modules designed to help you find…
DrugPatentWatch publisher Yali Friedman, Ph.D. will be speaking at the 15th Edition Pharma Resource Planning and Portfolio Optimization Conference. The event is from from April 25-26, 2022 at the Sheraton…
This is a guest post by Ray Miller and Megan E. Bowers, Ph.D. at DLA Piper. Ray may be contacted at raymond.miller@dlapiper.com. When it comes to protecting therapeutic assets, I…
Drugs contain ingredients with therapeutic activity, so-called “active ingredients” as well as inactive ingredients. These inactive ingredients, called excipients, are included in oral products for various reasons, such as to…
DrugPatentWatch developed this course to help users better understand the complexities and common strategies around brand erosion and generic entry. The positive responses received made it apparent that the course…
DrugPatentWatch has been ranked the “Best Biopharmaceuticals Commercial Business Intelligence Platform” by Global Health & Pharma News This award is dedicated to honoring the innovation, determination and outstanding levels of…
DrugPatentWatch’s Custom Market Surveillance provides you with a robust platform to monitor your business opportunities from every angle. You’re monitoring your business, but you’re too busy to sift through data.…
Before the passage of the Biologic Patent Transparency Act DrugPatentWatch’s biologic patent data was cited as a reason why the law should not be passed. Thankfully, the Act advanced, and…
